ARANESP Side Effects

7019184-4 | Leg Amputation, Peripheral Ischaemia, Thrombosis
on Sep 14, 2010 Male patient from BELGIUM , weighting 207.2 lb, was diagnosed with anaemia of malignant disease and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: leg amputation, peripheral ischaemia, thrombosis. Aranesp dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

7016914-2 | Anaemia, Anal Fissure, Aplasia Pure Red Cell, Colonic Polyp, Cystitis, Fatigue, Gastritis Erosive, Haemorrhoids
Patient was taking Aranesp (View Usage). Patient had the following side effects: anaemia, anal fissure, aplasia pure red cell, colonic polyp (What is colonic polyp?), cystitis, fatigue, gastritis erosive, haemorrhoids on Sep 15, 2010 from GERMANY Additional patient health information: Female patient , weighting 198.4 lb, was diagnosed with renal failure chronic and. Aranesp dosage: . During the same period patient was treated with GLURENORM (View Glurenorm Review and Glurenorm Label ), METAMIZOLE (View Metamizole Review and Metamizole Label ), MARCUMAR (View Marcumar Review and Marcumar Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), CARVEDILOL (View Carvedilol Review and Carvedilol Label ), ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ). Patient was hospitalized.

7013622-9 | Aplasia Pure Red Cell, Asthenia, Decreased Appetite, Erythroblast Count Decreased, Fatigue, Haemoglobin Decreased, Thrombocytopenia
Adverse event was reported on Sep 16, 2010 by a Male patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with renal failure chronic and. Location: GERMANY , 58 years of age, After Aranesp was administered, patient had the following side effects: aplasia pure red cell, asthenia, decreased appetite, erythroblast count decreased, fatigue, haemoglobin decreased, thrombocytopenia. During the same period patient was treated with CELLCEPT (View Cellcept Review and Cellcept Label ), MINERAL TAB (View Mineral Tab Review and Mineral Tab Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ACTOS (View Actos Review and Actos Label ), ROCALTROL (View Rocaltrol Review and Rocaltrol Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), IRON (View Iron Review and Iron Label ). Patient was hospitalized.

7013621-7 | Epistaxis
on Sep 16, 2010 Male patient from FRANCE , 86 years of age, weighting 121.3 lb, was diagnosed with anaemia and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: epistaxis. Aranesp dosage: . During the same period patient was treated with LUCENTIS (View Lucentis Review and Lucentis Label ). Patient was hospitalized.


7010938-7 | Anaemia, Anti-erythropoietin Antibody Positive, Aplasia Pure Red Cell, Bone Marrow Myelogram Abnormal, Therapeutic Response Decreased
on Sep 16, 2010 Male patient from UNITED STATES , weighting 134.5 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). Patient had the following side effects: anaemia, anti-erythropoietin antibody positive, aplasia pure red cell, bone marrow myelogram abnormal, therapeutic response decreased. Aranesp dosage: . During the same period patient was treated with EPOGEN (View Epogen Review and Epogen Label ), ROCALTROL (View Rocaltrol Review and Rocaltrol Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), OSELTAMIVIR (View Oseltamivir Review and Oseltamivir Label ), LOPRESSOR (View Lopressor Review and Lopressor Label ), COZAAR (View Cozaar Review and Cozaar Label ), PROTONIX (View Protonix Review and Protonix Label ), MINOXIDIL (View Minoxidil Review and Minoxidil Label ). Patient was hospitalized.

6994557-4 | Anaemia, Aplasia Pure Red Cell
Patient was taking Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: anaemia, aplasia pure red cell on Sep 05, 2010 from GERMANY Additional patient health information: Female patient , 71 years of age, was diagnosed with renal failure chronic and. Aranesp dosage: . Patient was hospitalized.

6994365-4 | Anaemia, Aplasia Pure Red Cell, Injection Site Pain, Injection Site Pruritus, Therapeutic Response Decreased
Adverse event was reported on Sep 09, 2010 by a Female patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with renal failure chronic and. Location: BELGIUM , 78 years of age, weighting 83.78 lb, Patient experienced the following unwanted or unexpected effects: anaemia, aplasia pure red cell, injection site pain, injection site pruritus, therapeutic response decreased. During the same period patient was treated with ENBREL (View Enbrel Review and Enbrel Label ).

6985172-7 | Haemoglobin Increased
on Sep 07, 2010 Male patient from GERMANY , weighting 227.1 lb, was diagnosed with dialysis (What is dialysis?) and was treated with Aranesp (View Usage). Patient had the following side effects: haemoglobin increased. Aranesp dosage: .

6978457-1 | Anaemia, Dyspnoea Exertional, Lethargy, Myeloproliferative Disorder, Somnolence, Weight Decreased
on Sep 02, 2010 Male patient from UNITED STATES , weighting 202.8 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: anaemia, dyspnoea exertional, lethargy, myeloproliferative disorder, somnolence, weight decreased. Aranesp dosage: . During the same period patient was treated with METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), ANAGRELIDE HCL (View Anagrelide Hcl Review and Anagrelide Hcl Label ), HYDROXYUREA (View Hydroxyurea Review and Hydroxyurea Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), NEXIUM (View Nexium Review and Nexium Label ), IRON (View Iron Review and Iron Label ), PROCRIT (View Procrit Review and Procrit Label ).

6977315-6 | Anaemia, Aplasia Pure Red Cell
Patient was taking Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, aplasia pure red cell on Sep 01, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 156.1 lb, was diagnosed with dialysis (What is dialysis?) and. Aranesp dosage: . During the same period patient was treated with EPOGEN (View Epogen Review and Epogen Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), LABETALOL HYDROCHLORIDE (View Labetalol Hydrochloride Review and Labetalol Hydrochloride Label ), LOVAZA (View Lovaza Review and Lovaza Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), GENTAMYCIN SULFATE (View Gentamycin Sulfate Review and Gentamycin Sulfate Label ), CALCIUM CARBONATE (View Calcium Carbonate Review and Calcium Carbonate Label ). Patient was hospitalized.

6976349-5 | Agitation, Anxiety, Epistaxis, Haemoglobin Decreased, Haemorrhage, Hospitalisation, Nervousness, Surgery
Adverse event was reported on Sep 02, 2010 by a Female patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with anaemia and. Location: SPAIN , 78 years of age, Patient had the following side effects: agitation, anxiety (What is anxiety?), epistaxis, haemoglobin decreased, haemorrhage, hospitalisation, nervousness, surgery (What is surgery?). During the same period patient was treated with NOVOSEVEN (View Novoseven Review and Novoseven Label ). Patient was hospitalized.

6966006-3 | Arthralgia, Back Pain, Pain In Extremity
on Aug 26, 2010 Female patient from AUSTRALIA , weighting 155.2 lb, was treated with Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: arthralgia, back pain (What is back pain?), pain in extremity. Aranesp dosage: . During the same period patient was treated with AVINZA (View Avinza Review and Avinza Label ), LAMICTAL (View Lamictal Review and Lamictal Label ), LITHIUM CARBONATE (View Lithium Carbonate Review and Lithium Carbonate Label ), NATRILIX SLOW RELEASE (View Natrilix - Slow Release Review and Natrilix - Slow Release Label ), NOSPAN (View Nospan Review and Nospan Label ), KARVEA (View Karvea Review and Karvea Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), TROXSIN (View Troxsin Review and Troxsin Label ).

6963951-X | Refractory Anaemia, Therapeutic Response Decreased
on Aug 25, 2010 Female patient from CANADA , weighting 149.9 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: refractory anaemia, therapeutic response decreased. Aranesp dosage: . During the same period patient was treated with CELLCEPT (View Cellcept Review and Cellcept Label ), SODIUM PHOSPHATE (32 P) (View Sodium Phosphate (32 P) Review and Sodium Phosphate (32 P) Label ), ONE ALPHA (View One-alpha Review and One-alpha Label ), CALCIUM/VITAMIN D (View Calcium/vitamin D Review and Calcium/vitamin D Label ), SODIUM BICARBONATE (View Sodium Bicarbonate Review and Sodium Bicarbonate Label ), AVAPRO (View Avapro Review and Avapro Label ), LASIX (View Lasix Review and Lasix Label ), NORVASC (View Norvasc Review and Norvasc Label ).

6959082-5 | Anaemia, Aplasia Pure Red Cell
Patient was taking Aranesp (View Usage). Patient had the following side effects: anaemia, aplasia pure red cell on Aug 20, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 156.1 lb, was diagnosed with dialysis (What is dialysis?) and. Aranesp dosage: . During the same period patient was treated with EPOGEN (View Epogen Review and Epogen Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), LABETALOL HYDROCHLORIDE (View Labetalol Hydrochloride Review and Labetalol Hydrochloride Label ), LOVAZA (View Lovaza Review and Lovaza Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), GENTAMYCIN SULFATE (View Gentamycin Sulfate Review and Gentamycin Sulfate Label ), CALCIUM CARBONATE (View Calcium Carbonate Review and Calcium Carbonate Label ). Patient was hospitalized.

6946181-7 | Haemorrhage, Needle Issue, Underdose
Adverse event was reported on Aug 20, 2010 by a Male patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with dialysis (What is dialysis?) and. Location: SWEDEN , 67 years of age, After Aranesp was administered, patient had the following side effects: haemorrhage, needle issue, underdose.

6946028-9 | Anti-erythropoietin Antibody Positive, Aplasia Pure Red Cell, Blood Count Abnormal, Decreased Appetite, Performance Status Decreased, Respiratory Distress, Therapeutic Response Decreased
on Aug 19, 2010 Male patient from GERMANY , weighting 129.6 lb, was diagnosed with dialysis (What is dialysis?) and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: anti-erythropoietin antibody positive, aplasia pure red cell, blood count abnormal, decreased appetite, performance status decreased, respiratory distress, therapeutic response decreased. Aranesp dosage: . During the same period patient was treated with SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), FERRLECIT (View Ferrlecit Review and Ferrlecit Label ), FOSRENOL (View Fosrenol Review and Fosrenol Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), CINACALCET HYDROCHLORIDE (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ), DREISAVIT (View Dreisavit Review and Dreisavit Label ). Patient was hospitalized.

6943684-6 | Arthralgia, Back Pain, Pain In Extremity
on Aug 18, 2010 Female patient from AUSTRALIA , weighting 155.2 lb, was treated with Aranesp (View Usage). Patient had the following side effects: arthralgia, back pain (What is back pain?), pain in extremity. Aranesp dosage: . During the same period patient was treated with AVINZA (View Avinza Review and Avinza Label ), LAMICTAL (View Lamictal Review and Lamictal Label ), LITHIUM CARBONATE (View Lithium Carbonate Review and Lithium Carbonate Label ), NATRILIX SLOW RELEASE (View Natrilix - Slow Release Review and Natrilix - Slow Release Label ), NOSPAN (View Nospan Review and Nospan Label ), KARVEA (View Karvea Review and Karvea Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), TROXSIN (View Troxsin Review and Troxsin Label ).

6941543-6 | Haemoglobin Decreased, Otitis Media Acute, Platelet Count Decreased, Red Blood Cell Count Decreased, White Blood Cell Count Decreased
Patient was taking Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: haemoglobin decreased, otitis media acute, platelet count decreased, red blood cell count decreased, white blood cell count decreased on Aug 17, 2010 from ESTONIA Additional patient health information: Female patient , child 3 years of age, was diagnosed with renal failure chronic and. Aranesp dosage: . During the same period patient was treated with ENALAPRIL (View Enalapril Review and Enalapril Label ), NORVASC (View Norvasc Review and Norvasc Label ), CALCITRIOL (View Calcitriol Review and Calcitriol Label ).

6941528-X | Burning Sensation, Malaise, Nausea, Pain, Pruritus
Adverse event was reported on Aug 17, 2010 by a Male patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with renal failure chronic and. Location: GERMANY , weighting 277.8 lb, Patient experienced the following unwanted or unexpected effects: burning sensation, malaise, nausea (What is nausea?), pain (What is pain?), pruritus. During the same period patient was treated with BISOPROLOL (View Bisoprolol Review and Bisoprolol Label ), DECORTIN H (View Decortin-h Review and Decortin-h Label ), EINSALPHA (View Einsalpha Review and Einsalpha Label ), IDEOS (View Ideos Review and Ideos Label ), AZATHIOPRINE (View Azathioprine Review and Azathioprine Label ), NEXIUM (View Nexium Review and Nexium Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ).

6941280-8 | Agitation, Epistaxis, Haemoglobin Decreased, Haemorrhage, Hospitalisation, Nervousness, Surgery
on Aug 17, 2010 Female patient from SPAIN , 78 years of age, was diagnosed with anaemia and was treated with Aranesp (View Usage). Patient had the following side effects: agitation, epistaxis, haemoglobin decreased, haemorrhage, hospitalisation, nervousness, surgery (What is surgery?). Aranesp dosage: . During the same period patient was treated with NOVOSEVEN (View Novoseven Review and Novoseven Label ). Patient was hospitalized.

6940851-2 | Hyperparathyroidism, Lower Respiratory Tract Infection
on Aug 16, 2010 Female patient from UNITED KINGDOM , 24 years of age, weighting 90.39 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: hyperparathyroidism, lower respiratory tract infection. Aranesp dosage: . During the same period patient was treated with EPREX (View Eprex Review and Eprex Label ), BLOOD CELLS, PACKED HUMAN (View Blood Cells, Packed Human Review and Blood Cells, Packed Human Label ).

6932553-3 | Anaemia, Aplasia Pure Red Cell, Bacterial Infection, Cardiac Failure, Graft Dysfunction, Haemoglobin Decreased, Red Blood Cell Count Decreased, Reticulocyte Count Decreased, Staphylococcal Sepsis
Patient was taking Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, aplasia pure red cell, bacterial infection (What is bacterial infection?), cardiac failure, graft dysfunction, haemoglobin decreased, red blood cell count decreased, reticulocyte count decreased, staphylococcal sepsis on Aug 11, 2010 from SWEDEN Additional patient health information: Male patient , weighting 184.1 lb, was diagnosed with renal failure chronic and. Aranesp dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), FOLACIN (View Folacin Review and Folacin Label ), FUROSEMID (View Furosemid Review and Furosemid Label ), KREDEX (View Kredex Review and Kredex Label ), PROSCAR (View Proscar Review and Proscar Label ), CINACALCET HYDROCHLORIDE (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ), DIGOXIN (View Digoxin Review and Digoxin Label ). Patient was hospitalized.

6932552-1 | Anti-erythropoietin Antibody Positive, Aplasia Pure Red Cell, Decreased Appetite, Performance Status Decreased, Respiratory Distress, Therapeutic Response Decreased
Adverse event was reported on Aug 11, 2010 by a Male patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with dialysis (What is dialysis?) and. Location: GERMANY , weighting 129.6 lb, Patient had the following side effects: anti-erythropoietin antibody positive, aplasia pure red cell, decreased appetite, performance status decreased, respiratory distress, therapeutic response decreased. During the same period patient was treated with SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), FERRLECIT (View Ferrlecit Review and Ferrlecit Label ), FOSRENOL (View Fosrenol Review and Fosrenol Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), CINACALCET HYDROCHLORIDE (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ), DREISAVIT (View Dreisavit Review and Dreisavit Label ). Patient was hospitalized.

6926140-0 | Anaemia, Aplasia Pure Red Cell, Bone Marrow Myelogram Abnormal, Therapeutic Response Decreased
on Aug 06, 2010 Male patient from UNITED STATES , weighting 134.5 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: anaemia, aplasia pure red cell, bone marrow myelogram abnormal, therapeutic response decreased. Aranesp dosage: . During the same period patient was treated with EPOETIN ALFA (View Epoetin Alfa Review and Epoetin Alfa Label ), ROCALTROL (View Rocaltrol Review and Rocaltrol Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), OSELTAMIVIR (View Oseltamivir Review and Oseltamivir Label ), LOPRESSOR (View Lopressor Review and Lopressor Label ), COZAAR (View Cozaar Review and Cozaar Label ), PROTONIX (View Protonix Review and Protonix Label ), MINOXIDIL (View Minoxidil Review and Minoxidil Label ). Patient was hospitalized.

6924051-8 | Intermittent Claudication
on Aug 12, 2010 Male patient from NETHERLANDS , 64 years of age, weighting 163.8 lb, was diagnosed with anaemia of malignant disease and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: intermittent claudication. Aranesp dosage: . During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), CODEINE PHOSPHATE AND ACETAMINOPHEN (View Codeine Phosphate And Acetaminophen Review and Codeine Phosphate And Acetaminophen Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), RIVOTRIL (View Rivotril Review and Rivotril Label ), TRAMADOL HYDROCHLORIDE (View Tramadol Hydrochloride Review and Tramadol Hydrochloride Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), DEPAKENE (View Depakene Review and Depakene Label ).

6917480-X | Haemorrhage, Needle Issue, Underdose
Patient was taking Aranesp (View Usage). Patient had the following side effects: haemorrhage, needle issue, underdose on Aug 03, 2010 from SWEDEN Additional patient health information: Male patient , 67 years of age, was diagnosed with dialysis (What is dialysis?) and. Aranesp dosage: .

6914747-6 | Paralysis
Adverse event was reported on Aug 02, 2010 by a Female patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with renal failure chronic and. Location: GERMANY , 79 years of age, weighting 178.6 lb, After Aranesp was administered, patient had the following side effects: paralysis (What is paralysis?).

6911094-3 | Anti-erythropoietin Antibody Positive, Aplasia Pure Red Cell, Blood Glucose Abnormal, Fibula Fracture, Renal Transplant, Therapeutic Response Decreased
on Jul 27, 2010 Male patient from UNITED KINGDOM , weighting 198.4 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: anti-erythropoietin antibody positive, aplasia pure red cell, blood glucose abnormal, fibula fracture, renal transplant, therapeutic response decreased. Aranesp dosage: . During the same period patient was treated with EPREX (View Eprex Review and Eprex Label ), ALFACALCIDOL (View Alfacalcidol Review and Alfacalcidol Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), ATORVASTATIN (View Atorvastatin Review and Atorvastatin Label ), BENDROFLUAZIDE (View Bendrofluazide Review and Bendrofluazide Label ), DOXAZOSIN (View Doxazosin Review and Doxazosin Label ).

6909690-2 | Anaemia, Dyspnoea Exertional, Lethargy, Myeloproliferative Disorder, Somnolence, Weight Decreased
on Jul 29, 2010 Male patient from UNITED STATES , weighting 202.8 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). Patient had the following side effects: anaemia, dyspnoea exertional, lethargy, myeloproliferative disorder, somnolence, weight decreased. Aranesp dosage: . During the same period patient was treated with METOPROLOL (View Metoprolol Review and Metoprolol Label ), ANAGRELIDE HCL (View Anagrelide Hcl Review and Anagrelide Hcl Label ), HYDROXYUREA (View Hydroxyurea Review and Hydroxyurea Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), NEXIUM (View Nexium Review and Nexium Label ), IRON (View Iron Review and Iron Label ), PROCRIT (View Procrit Review and Procrit Label ).

6896318-3 | Pancreatitis
Patient was taking Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: pancreatitis on Jul 26, 2010 from AUSTRALIA Additional patient health information: Female patient , weighting 127.9 lb, was diagnosed with anaemia of malignant disease and. Aranesp dosage: . During the same period patient was treated with ROCALTROL (View Rocaltrol Review and Rocaltrol Label ), THALIDOMIDE (View Thalidomide Review and Thalidomide Label ), INDERAL (View Inderal Review and Inderal Label ), LIPITOR (View Lipitor Review and Lipitor Label ). Patient was hospitalized.

6895991-3 | Anaemia, Therapeutic Response Decreased
Adverse event was reported on Jul 27, 2010 by a Male patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with renal failure chronic and. Location: UNITED STATES , weighting 145.1 lb, Patient experienced the following unwanted or unexpected effects: anaemia, therapeutic response decreased. During the same period patient was treated with PROCRIT (View Procrit Review and Procrit Label ), LASIX (View Lasix Review and Lasix Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), IMURAN (View Imuran Review and Imuran Label ), LANTUS (View Lantus Review and Lantus Label ), KLOR CON (View Klor-con Review and Klor-con Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), CENTRUM (View Centrum Review and Centrum Label ).

6894757-8 | Hyperparathyroidism, Lower Respiratory Tract Infection
on Jul 27, 2010 Female patient from UNITED KINGDOM , 24 years of age, weighting 90.39 lb, was diagnosed with dialysis (What is dialysis?) and was treated with Aranesp (View Usage). Patient had the following side effects: hyperparathyroidism, lower respiratory tract infection. Aranesp dosage: . During the same period patient was treated with EPREX (View Eprex Review and Eprex Label ), BLOOD CELLS, PACKED HUMAN (View Blood Cells, Packed Human Review and Blood Cells, Packed Human Label ).

6885221-0 | Asthenia, Blood Calcium Decreased, Blood Parathyroid Hormone Increased, Convulsion, Dysphagia, Fall, Fatigue, Haemoglobin Decreased, Hypomagnesaemia
on Jul 23, 2010 Female patient from UNITED STATES , weighting 130.1 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: asthenia, blood calcium decreased, blood parathyroid hormone increased, convulsion, dysphagia, fall (What is fall?), fatigue, haemoglobin decreased, hypomagnesaemia. Aranesp dosage: . During the same period patient was treated with ATENOLOL (View Atenolol Review and Atenolol Label ), PREMARIN (View Premarin Review and Premarin Label ), CALCITRIOL (View Calcitriol Review and Calcitriol Label ), LAMICTAL (View Lamictal Review and Lamictal Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), LASIX (View Lasix Review and Lasix Label ), MULTI VITAMINS (View Multi-vitamins Review and Multi-vitamins Label ), LOMOTIL (View Lomotil Review and Lomotil Label ). Patient was hospitalized.

6875034-8 | Blood Glucose Increased
Patient was taking Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: blood glucose increased on Jul 16, 2010 from UNITED STATES Additional patient health information: Male patient , 87 years of age, was diagnosed with renal failure chronic and. Aranesp dosage: .

6868330-1 | Aplasia Pure Red Cell, Decreased Appetite, Performance Status Decreased, Respiratory Distress, Therapeutic Response Decreased
Adverse event was reported on Jul 19, 2010 by a Male patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with dialysis (What is dialysis?) and. Location: GERMANY , weighting 129.6 lb, Patient had the following side effects: aplasia pure red cell, decreased appetite, performance status decreased, respiratory distress, therapeutic response decreased. During the same period patient was treated with SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), FERRLECIT (View Ferrlecit Review and Ferrlecit Label ), FOSRENOL (View Fosrenol Review and Fosrenol Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), CINACALCET HYDROCHLORIDE (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ), DREISAVIT (View Dreisavit Review and Dreisavit Label ). Patient was hospitalized.

6862786-6 | Cerebrovascular Disorder
on Jul 15, 2010 Female patient from GERMANY , 56 years of age, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: cerebrovascular disorder. Aranesp dosage: .

6861461-1 | Anaemia, Aplasia Pure Red Cell, Bacterial Infection, Cardiac Failure, Graft Dysfunction, Haemoglobin Decreased, Red Blood Cell Count Decreased, Reticulocyte Count Decreased, Staphylococcal Sepsis
on Jul 13, 2010 Male patient from SWEDEN , weighting 184.1 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, aplasia pure red cell, bacterial infection (What is bacterial infection?), cardiac failure, graft dysfunction, haemoglobin decreased, red blood cell count decreased, reticulocyte count decreased, staphylococcal sepsis. Aranesp dosage: . During the same period patient was treated with TROMBYL (View Trombyl Review and Trombyl Label ), FOLACIN (View Folacin Review and Folacin Label ), FUROSEMID (View Furosemid Review and Furosemid Label ), KREDEX (View Kredex Review and Kredex Label ), PROSCAR (View Proscar Review and Proscar Label ), CINACALCET HYDROCHLORIDE (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ), DIGOXIN (View Digoxin Review and Digoxin Label ). Patient was hospitalized.

6860057-5 | Peritonitis
Patient was taking Aranesp (View Usage). Patient had the following side effects: peritonitis on Jul 12, 2010 from SPAIN Additional patient health information: Female patient , 65 years of age, weighting 158.7 lb, was diagnosed with dialysis (What is dialysis?) and. Aranesp dosage: . During the same period patient was treated with IRON (View Iron Review and Iron Label ).

6843928-5 | Aplasia Pure Red Cell
Adverse event was reported on Jul 05, 2010 by a Female patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with renal failure chronic and. Location: UNITED KINGDOM , 81 years of age, weighting 103.6 lb, After Aranesp was administered, patient had the following side effects: aplasia pure red cell. During the same period patient was treated with EPREX (View Eprex Review and Eprex Label ), NEORECORMON (View Neorecormon Review and Neorecormon Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), ISOSORBIDE MONONITRADE (View Isosorbide Mononitrade Review and Isosorbide Mononitrade Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), OROVITE (View Orovite Review and Orovite Label ), CALCIUM ACETATE (View Calcium Acetate Review and Calcium Acetate Label ), PRAVASTATIN (View Pravastatin Review and Pravastatin Label ).

6835700-7 | Bacterial Infection, Haemoglobin Decreased, Red Blood Cell Count Decreased
on Jul 06, 2010 Male patient from SWEDEN , 83 years of age, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: bacterial infection (What is bacterial infection?), haemoglobin decreased, red blood cell count decreased. Aranesp dosage: .

6833411-5 | Myocardial Infarction, Pulmonary Oedema, Renal Failure
on Jul 03, 2010 Female patient from UNITED STATES , 93 years of age, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). Patient had the following side effects: myocardial infarction, pulmonary oedema, renal failure. Aranesp dosage: . During the same period patient was treated with EPOGEN (View Epogen Review and Epogen Label ), COZAAR (View Cozaar Review and Cozaar Label ), HCT (View Hct Review and Hct Label ), NORVASC (View Norvasc Review and Norvasc Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), LIPITOR (View Lipitor Review and Lipitor Label ), PAXIL (View Paxil Review and Paxil Label ).

6815682-4 | Encephalitis, Hallucination, Visual, Leukoencephalopathy, Vision Blurred
Patient was taking Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: encephalitis (What is encephalitis?), hallucination, visual, leukoencephalopathy, vision blurred on Jun 25, 2010 from FRANCE Additional patient health information: Male patient , weighting 136.7 lb, . Aranesp dosage: . During the same period patient was treated with CHLORAMBUCIL (View Chlorambucil Review and Chlorambucil Label ).

6814388-5 | Aplasia Pure Red Cell, Decreased Appetite, Performance Status Decreased, Respiratory Distress, Therapeutic Response Decreased
Adverse event was reported on Jun 24, 2010 by a Male patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with dialysis (What is dialysis?) and. Location: GERMANY , weighting 129.6 lb, Patient experienced the following unwanted or unexpected effects: aplasia pure red cell, decreased appetite, performance status decreased, respiratory distress, therapeutic response decreased. During the same period patient was treated with SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), FERRLECIT (View Ferrlecit Review and Ferrlecit Label ), FOSRENOL (View Fosrenol Review and Fosrenol Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), CINACALCET HYDROCHLORIDE (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ), DREISAVIT (View Dreisavit Review and Dreisavit Label ).

6813664-X | Anaemia, Anisocytosis, Macrocytosis, Marrow Hyperplasia, Poikilocytosis, Polychromasia, Therapeutic Response Decreased
on Jun 22, 2010 Male patient from UNITED STATES , weighting 145.1 lb, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). Patient had the following side effects: anaemia, anisocytosis, macrocytosis, marrow hyperplasia, poikilocytosis, polychromasia, therapeutic response decreased. Aranesp dosage: . During the same period patient was treated with PROCRIT (View Procrit Review and Procrit Label ), LASIX (View Lasix Review and Lasix Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), IMURAN (View Imuran Review and Imuran Label ), LANTUS (View Lantus Review and Lantus Label ), KLOR CON (View Klor-con Review and Klor-con Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), CENTRUM (View Centrum Review and Centrum Label ).

6811519-8 | Myocardial Infarction, Pulmonary Oedema, Renal Failure
on Jun 22, 2010 Female patient from UNITED STATES , 93 years of age, was diagnosed with renal failure chronic and was treated with Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: myocardial infarction, pulmonary oedema, renal failure. Aranesp dosage: . During the same period patient was treated with EPOGEN (View Epogen Review and Epogen Label ), COZAAR (View Cozaar Review and Cozaar Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), NORVASC (View Norvasc Review and Norvasc Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), LIPITOR (View Lipitor Review and Lipitor Label ), PAXIL (View Paxil Review and Paxil Label ).

6811070-5 | Therapeutic Response Decreased
Patient was taking Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: therapeutic response decreased on Jun 24, 2010 from FRANCE Additional patient health information: Female patient , 94 years of age, was diagnosed with myelodysplastic syndrome and. Aranesp dosage: . During the same period patient was treated with GRANOCYTE (View Granocyte Review and Granocyte Label ), REVLIMID (View Revlimid Review and Revlimid Label ).

6810467-7 | Anaemia, Gastrointestinal Angiodysplasia Haemorrhagic
Adverse event was reported on Jun 22, 2010 by a Male patient taking Aranesp (View Usage) (Dosage: ) was diagnosed with renal failure chronic and. Location: GERMANY , weighting 167.6 lb, Patient had the following side effects: anaemia, gastrointestinal angiodysplasia haemorrhagic. During the same period patient was treated with BLOPRESS (View Blopress Review and Blopress Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), PANTOPRAZOLE (View Pantoprazole Review and Pantoprazole Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), BENSERAZIDE HYDROCHLORIDE/LEVODOPA (View Benserazide Hydrochloride/levodopa Review and Benserazide Hydrochloride/levodopa Label ), CALCIUM ACETATE (View Calcium Acetate Review and Calcium Acetate Label ), TORASEMIDE (View Torasemide Review and Torasemide Label ), IRON DEXTRAN (View Iron Dextran Review and Iron Dextran Label ).

6796324-3 | Anaemia, Bradycardia, Deep Vein Thrombosis
on Jun 17, 2010 Female patient from UNITED STATES , weighting 214.3 lb, was diagnosed with anaemia of malignant disease, multiple myeloma (What is multiple myeloma?) and was treated with Aranesp (View Usage). After Aranesp was administered, patient had the following side effects: anaemia, bradycardia, deep vein thrombosis (What is deep vein thrombosis?). Aranesp dosage: . During the same period patient was treated with THALIDOMIDE (View Thalidomide Review and Thalidomide Label ), DECADRON (View Decadron Review and Decadron Label ), ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), COUMADIN (View Coumadin Review and Coumadin Label ), ZOMETA (View Zometa Review and Zometa Label ), MULTI VITAMINS (View Multi-vitamins Review and Multi-vitamins Label ).

6792476-X | Anaemia, Aplasia Pure Red Cell, Therapeutic Response Decreased
on Jun 17, 2010 Male patient from GERMANY , weighting 255.7 lb, was diagnosed with anaemia of malignant disease and was treated with Aranesp (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, aplasia pure red cell, therapeutic response decreased. Aranesp dosage: . During the same period patient was treated with FLECAINIDE ACETATE (View Flecainide Acetate Review and Flecainide Acetate Label ), SODIUM FERRIC GLUCONATE COMPLEX (View Sodium Ferric Gluconate Complex Review and Sodium Ferric Gluconate Complex Label ), BISOPROLOL (View Bisoprolol Review and Bisoprolol Label ), CALCIUM ACETATE (View Calcium Acetate Review and Calcium Acetate Label ), SODIUM BICARBONATE (View Sodium Bicarbonate Review and Sodium Bicarbonate Label ), PANTOZOL (View Pantozol Review and Pantozol Label ), EPOETIN ALFA (View Epoetin Alfa Review and Epoetin Alfa Label ).

6792474-6 | Anaemia, Arteriovenous Malformation, Asthenia, Bone Marrow Failure, Gastric Haemorrhage, Gastritis, Hyperphosphataemia, Hypotension
Patient was taking Aranesp (View Usage). Patient had the following side effects: anaemia, arteriovenous malformation (What is arteriovenous malformation?), asthenia, bone marrow failure, gastric haemorrhage, gastritis, hyperphosphataemia, hypotension on Jun 17, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 128.1 lb, was diagnosed with renal failure chronic and. Aranesp dosage: . During the same period patient was treated with IMURAN (View Imuran Review and Imuran Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), CALCITRIOL (View Calcitriol Review and Calcitriol Label ), CALCIUM WITH VITAMIN D (View Calcium With Vitamin D Review and Calcium With Vitamin D Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ). Patient was hospitalized.